Get the Stockscreener App
12.18
1.00%
0.14
Greenwich Lifesciences Inc stock is traded at $12.18, with a volume of 4,063.
It is up +1.00% in the last 24 hours and up +0.00% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$12.04
Open:
$12.21
24h Volume:
4,063
Relative Volume:
0.12
Market Cap:
$158.26M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-17.40
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-1.78%
1M Performance:
+0.00%
6M Performance:
-17.84%
1Y Performance:
-7.60%
1-Day Range:
$12.03
$12.31
1-Week Range:
$11.87
$12.95
52-Week Range:
$10.52
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
12.31 | 158.26M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.05 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.47 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.04 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.17 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 5.1% in January - MarketBeat
Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat
Learn to Evaluate (GLSI) using the Charts - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat
What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World
Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK
Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan
Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha
(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance
Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com
Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe - GlobeNewswire
Major Breakthrough: Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland - GlobeNewswire
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences gains after GP2 commercial manufacturing update - MSN
Barclays PLC Has $123,000 Stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Bullish Greenwich LifeSciences Insiders Loaded Up On US$3.39m Of Stock - Yahoo Finance
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 - GlobeNewswire
Harvard, Johns Hopkins Join Greenwich LifeSciences' Phase III Breast Cancer Vaccine Trial - StockTitan
Greenwich LifeSciences stock gains on GP2 update (GLSI) - Seeking Alpha
Greenwich LifeSciences Provides Update on Commercial Manufacturing - GlobeNewswire
Greenwich LifeSciences Achieves Major Manufacturing Milestone for Breast Cancer Immunotherapy GP2 - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) - Marketscreener.com
Long Term Trading Analysis for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 - GlobeNewswire
Greenwich LifeSciences expands trial sites in Germany - Investing.com India
Greenwich Lifesciences Announces Partnership with GBG in Germany for Flamingo-01 - Marketscreener.com
Greenwich LifeSciences CEO acquires $31,275 in common stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO acquires $31,275 in common stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares - MarketBeat
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus.com
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France - The Manila Times
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across France with Unicancer Network - StockTitan
Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock By Investing.com - Investing.com Australia
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):